The Cap Table

For healthcare startups, AI is now table stakes. But what does that really mean for care providers, patients, and investors?

In our latest episode of The Cap Table, Adam Seabrook joined us to talk about how the winners in the healthcare space will be decided by GTM strategy, not just AI technology, how he's learned to evaluate healthcare companies, and where he sees healthcare investing headed next.

Adam Seabrook is a partner at B Capital, where he leads healthcare and digital health investing. A Canadian-born Cornell engineer who started out wanting to build prosthetics, he went on to work at two early-stage healthcare startups and at Imaging Advantage before joining B Capital out of business school at the University of Chicago.

Inside this conversation:
— Adam walks through his path from engineering to venture and what a normal day looks like when most of it is spent learning from founders.
— He explains why he has long favored fee-for-service over value-based care, and why AI could bring value-based models back into fashion.
— He makes the case that AI's biggest ROI is freeing clinicians to deliver more human care, and that virtual specialty care gives patients outside big cities access to experts.
— He uses PicnicHealth to show how companies build defensibility through applications on top of their technology, and explains why healthcare's economics (high switching costs, long sales cycles, one-time outcomes) deserve different valuations than software.
— He covers when digital health companies start to look like private equity targets, how an engineering mindset shapes his founder diligence, and why he believes wearable data went from fad to future.
— A final lightning round tackles GLP-1s versus virtual care, fee-for- service care, healthspan, and LA versus San Francisco.

If you invest in healthcare or want to understand where the sector is heading, this one is worth your time.

The Cap Table is a podcast by Affinity.

🔗 Affinity: https://buff.ly/11jDF7y
🔗 B Capital: https://b.capital/
🔗 Follow B Capital: https://www.linkedin.com/company/b-capital-group/
🔗 Connect with Adam Seabrook: https://www.linkedin.com/in/adam-seabrook/

Follow Affinity
YouTube:  @affinity_presents
YouTube (product):  @affinity_co
Instagram: https://www.instagram.com/affinity.hq/
LinkedIn: https://www.linkedin.com/company/project-affinity/

Disclaimer: The information in this podcast is informational in nature and does not take into consideration your personal circumstances. Therefore it is not intended to be a substitute for specific individualized financial, legal, or tax advice. To determine which strategy or investment may be suitable to you, consult the appropriate qualified professional before making any final decision.
  • (00:00) - Intro
  • (00:07) - Adam's path from Cornell engineering to B Capital
  • (01:03) - A day in the life leading healthcare investing
  • (02:11) - Value-based care versus the power law
  • (03:45) - Where AI delivers the biggest ROI in healthcare
  • (04:51) - Why specialty care is virtual health's next frontier
  • (06:07) - Data liquidity and PicnicHealth's go-to-market
  • (07:59) - What Imaging Advantage taught Adam about healthcare valuations
  • (10:28) - When digital health becomes a private equity asset
  • (11:52) - Thinking like an engineer when evaluating founders
  • (13:28) - The trend Adam once called hype: wearable data
  • (14:28) - Lightning round: GLP-1s, fee-for-service care, healthspan, LA vs. SF
  • (17:37) - The biggest GP mistake in healthcare

What is The Cap Table?

Talking through the big questions defining private capital.

Brought to you by Affinity Presents. Public conversations in private capital.

Hi, I'm Adam Seabrook, and this is The Cap Table.

Let's get right into it. The first question: Tell our viewers about yourself, from your roots in mechanical and biomedical engineering at Cornell to your mission now as a partner at B Capital.

I am Canadian originally, which is relevant as we start to talk about healthcare, because I came from a very different healthcare system. I was lucky enough to go to Cornell and study engineering there, and I thought I would develop new prosthetics. I ended up getting into the world of startups right out of undergrad and went to work at a teleradiology startup founded by another Cornell grad. I worked there for a number of years, and I worked for a clinical decision support startup as well. So, two roles at early-stage companies, and then I went to business school at the University of Chicago. When I left, I was lucky enough to be hired by B Capital to start working on healthcare.

All right, next question: What does a normal day look like leading healthcare and digital health at B Capital? How do you balance the clinical side of evaluating medical breakthroughs with the growth side of scaling a global portfolio?

Most of our day is spent learning about new things: new industries, new companies. We have the benefit of really talented people coming in and talking to us about what they're working on, and we get the benefit of learning a career's worth of information in a 30 or 60 minute pitch. So if you like learning, that's a really incredible place to be, and that's what we spend a huge portion of our day doing.

On the other part of the question, scaling a global portfolio while evaluating medical breakthroughs: when I started at B Capital, I was the only person focused on healthcare. Over time, we've built a really phenomenal team, and that's what's allowed us to scale. We hire people who are deeply knowledgeable about healthcare and want to have an impact on the industries that we're working in.

Next question: Value-Based Care versus the Power Law. You recently co-authored a piece questioning if value-based care can actually produce power law returns. Why is the VC math so much harder than it is for fee-for-service models?

Value-based care implies that the provider is going to take on some amount of financial risk for a patient's care. The piece that I wrote was really focused on whether it was viable for providers to do that, and to do it at scale in a way that met the return thresholds that venture capitalists need. Historically, it's been hard enough to scale a fee-for-service business and try to do something innovative and build a business from scratch without having to take on some new level of risk, like what you have to do in value-based care, where you absorb the financial risk that insurers have historically taken on themselves. So that piece really questioned that, and my view would be that fee-for-service is the better model, where you get paid specifically for the care that you deliver.

At the end of that piece, I started to talk about how AI would be integrated into care delivery and the administrative side of healthcare. Historically, I do think that fee-for-service has been a better model than value-based care. But as we see efficiencies roll through healthcare, I think you're going to see value-based care come back into fashion and become a viable model again, which is something that we're excited about.

Moving right along. In 2026, we've moved past the AI hype. For healthcare specifically, is AI's biggest ROI in diagnostics and finding the needle? Or is it in solving the massive administrative and workflow debt that is hitting hospitals?

I think the biggest ROI from AI is going to be getting the most out of the clinical teams that we have in place and delivering better outcomes to patients. To me, that means using AI to do everything from supporting the diagnosis to identifying or delivering the intervention. It means reducing friction in payments and engaging patients. If we can have AI help with all of those things, I think that frees the clinician up to deliver more empathetic, human care. At the end of the day, you get lower costs, better care for the patient, and a healthcare system that just feels more human, where today I think it feels very cold. Your visits are very fast. You move through them, and you're in and out of the doctor's office very quickly. So if we can deliver on that ROI, that'll be a huge impact for the healthcare system.

Virtual Specialty Care. With your investment in Synapticure, you're doubling down on virtual specialty care for neurodegenerative diseases. Why do you think specialty care is the next major frontier for virtual health rather than general primary care?

Primary care is a very local operation, and people say healthcare is local. It makes sense that a lot of our early digital health interventions went toward where a lot of people receive care. But as we've expanded into the next wave of virtual care, it's become clear that to deliver the best quality of care to patients, you need specialization. What virtual care allows you to do is get leverage on clinical specialists, so you don't have to treat patients locally. You can amortize the cost of high-cost clinicians over a large population across geographies. You can manage other components of a patient's care through lower-cost team members. You can coordinate care across a broader group of specialists. Ultimately, you end up with, again, lower cost of care for the patient and hopefully better outcomes. And you really increase access for patients who aren't in large city centers, where they might typically have access to these specialists at academic medical centers.

Moving on to the data liquidity problem. Through companies like PicnicHealth, you're working on patient-centered data. In 2026, is the biggest hurdle to precision medicine the technology itself, or the lack of interoperable data across the healthcare system?

We talk a lot about how technology is becoming table stakes, and one of the major differentiators for companies is actually how they go to market, not their technology stack. I think that's true whether you're talking about data interoperability, care delivery, revenue cycle operations, or pharmaceutical commercialization. Each of those companies is looking for a unique way to go to market.

In the example of PicnicHealth, before the LLM boom came along in 2022, they were building their own AI infrastructure to gather, structure, and abstract data from patient medical records, and that's something that's been really hard for healthcare for a long time. So it's a valuable, important piece of technology. But very early on, they realized that there would be other people trying to do the same thing and build similar technologies, and that the way they would stay ahead of the competition was to build applications on top of this really powerful technology.

One example of what they're doing is in clinical trials. They can run clinical trials for pharma companies where they are engaged with the patient for much longer, so they track patient outcomes for longer. They track a deeper level of data than traditional clinical sites, and they can do it at a much lower cost. So they're building defensibility on top of their technology stack by building applications that deliver real value to customers. That's how we see companies succeeding: you need great technology, but ultimately you need a really great business model on top of that as well.

Moving to the next question, the Role of Strategy. You were an early employee at Imaging Advantage, which focused on workflow optimization and roll-ups. What did that experience teach you about the terminal value of healthcare startups that a traditional software VC might miss?

Working at Imaging Advantage, we went into hospitals, and that exposed me to the chaos that exists within healthcare systems in the US. In general, one of the most important learnings is how healthcare actually operates in the US. I think that's something that can be lost on traditional software investors: the difference in the dynamics between selling software and ultimately delivering outcomes to patients.

One example is that most software startups run on recurring revenue with their customers. You expect those customers to renew year after year, and that brings repeatable revenue, which has allowed valuations to climb as investors can underwrite more predictable financials for these companies. In healthcare, I think we see a lot of the opposite dynamics in some ways. If you are treating a patient and that patient has a curable disease, if you do a great job, you cure the patient and you may never see them again. That's a good outcome in that case. You never see your customer again, which is very different from what a software company is hoping for.

We see these differences in dynamics in a bunch of different ways in healthcare. Medicare is one of the largest payers in the country, and they effectively set their own price for what they're going to pay for services, very different from what happens in software. The switching costs are extremely high for a bunch of reasons in healthcare, which means long sales cycles and slower growth. All of these things have an effect on cash flow for businesses, which should have an effect on how you value businesses.

And certainly in 2020 and 2021, we saw an influx of non-healthcare investors into the industry. Rock Health put out a great report about the number of new investors who were entering healthcare for the first time, and we saw valuations start to approach traditional software multiples and really distort the market. So I think some of those dynamics that exist in the operations of healthcare are things that get missed when you don't spend all of your time in the sector.

Moving right along to the next one: Healthcare Is a Durable Asset. Private equity is increasingly active in healthcare services. At what stage does a digital health company stop being a venture bet and start looking like a cash-flow-positive asset that a private equity shop would want to acquire?

I think the question kind of nails it. Historically, private equity has gotten interested when there's a clear line of sight and a pathway to being profitable and starting to generate cash, with no risk of more operational cash needing to go into the business. But one of the things that's interesting is that we are seeing private equity move earlier in acquiring businesses that can start to transform their more incumbent, services-heavy assets. So, looking at AI companies that can really increase the cash flow of existing businesses by automating a bunch of the human labor that goes into them today. We're seeing that in revenue cycle as one of the first areas where that's happened in healthcare. We are seeing it in a lot of back-office administrative workflows, and I'm certain we're going to start to see it in healthcare delivery more and more. So I would expect private equity to be buying businesses that are not necessarily cash-flow positive, but can really have an effect on the cash flow of the businesses that they may already own or are looking to buy.

Moving on to the next question, the Engineer's Conviction. You have a background in mechanical engineering. How does thinking like an engineer change how you evaluate a clinical founder, compared to an investor who comes purely from a finance background?

Thinking like an engineer is really about breaking down these big problems into smaller and smaller problems, then trying to get answers and continuing to move down the chain until you've broken the problem down and understand the risk as much as you possibly can. Ultimately, what we're trying to do is understand the risks that we're taking in any investment, because every early-stage company has risk, and evaluate whether that's a level of risk that we're comfortable taking.

I think the other component there is not being afraid to ask the dumb question. We're looking to invest in incredibly talented people. Most of the founders we've invested in are brilliant and exceptional at what they do, so when you're asking them a question, you're inherently asking someone who knows more. There's no risk to feeling dumb. You are going to be dumb compared to them in that context. That gives you the freedom to really ask any question that you want, and just keep asking the question that everyone might know the answer to and think is obvious, but you can keep asking until you feel comfortable. Thinking like an engineer is really about continuing to drill down until you have that level of comfort, and asking the dumb question if you need to.

Fill in the blank: What's a technology or medical trend that you once thought was hype, but now realize is actually the future of healthcare?

I think this one is wearable data, or personal healthcare data. Ten years ago, that might have been constrained to your Fitbit or Jawbone, and it is now much deeper than that. Every watch is tracking what you're doing. You can get genomic data, you can get gut microbiome data, you can get blood biomarkers from a number of different companies. I think all of that is interesting because we have better access to the data, and we are seeing models being developed that will help us better understand human biology and let us make better predictions for people's healthcare. Whereas ten years ago that felt like people tracking their fitness and maybe more of a fad, it's starting to feel like it'll have a real positive impact on healthcare over the coming decades.

The next section is titled The Lightning Round, so these are questions I'm supposed to answer quickly. Hopefully I can do that.

The first one: GLP-1s or virtual care, which is the bigger disruptor to the 2026 health economy?

I think the answer to that is GLP-1s, all day. We're seeing huge effects in obesity and weight loss, but we're also starting to see where this is going to have an effect in chronic disease, dementia, and addiction. So I think GLP-1s are going to have a huge impact on the healthcare economy, especially as competition brings reduced prices. That said, I am a huge fan of virtual care. I just think GLP-1s are so big for healthcare.

Fee-for-service: is it actually underrated by VCs right now?

I wrote that piece saying that I think fee-for-service is typically a better model than value-based care, so I don't want to say that it is overrated. But I think what's much more interesting is what the business model is going to be when we see AI integrated into healthcare. Fee-for-service as a model means you are being paid for a unit of your labor. If we start to integrate AI into healthcare, what we're going to find is that payers will eventually start to pay less if you're using less labor to deliver care. That means payers are going to capture all of the value of the efficiency gains. I don't think that's right. So I think for providers to capture that gain, they're going to have to explore new business models like value-based care and bundled payments, the kinds of things that allow them to capture the value of bringing efficiency to healthcare.

The most important health metric: life expectancy or healthspan?

Both of these are lagging indicators. If I had to choose one, I would say healthspan, which is the length of time you have a reasonable quality of life because you're healthy and don't have chronic diseases and other things slowing you down. But what I think is going to happen, with the increase in personalized data, is that you are going to have personalized healthcare metrics that do a better job of tracking you along your personal journey and steering you toward the types of actions you need to take to avoid specific things that we are predicting based on your healthcare data. I think that's much more interesting. It probably expands your healthspan, so maybe that's a point in favor of healthspan. But I think it's all going to be about personalized healthcare metrics relevant to your care journey.

Los Angeles versus San Francisco: which is the true capital of digital health?

I live in LA, so I'd love to be able to say LA, but I think San Francisco is clearly the tech hub, and it still is. There's a ton of healthcare happening here. That said, healthcare is local, and we're seeing it in San Francisco certainly, but also in LA, New York, DC, Boston, Chicago, and Austin. We're seeing it everywhere, and we go where the companies are.

The Expensive Mistake: What is the biggest error GPs are making in healthcare today?

This is a tough one to answer because it's all happening so fast, and it's playing out in real time. Different investors have different theses that they're investing against. What we think is going to be important for technology companies is finding the right business model and go-to-market strategy. For new companies, it's going to be about how you get your product into customer hands. How do you get paid for what you do? How do you build the ability... And those are going to be really important questions. When we look at AI companies, that's what we're looking for on top of technology, which we think is important and is starting to become table stakes in a lot of cases. Eventually, you need to prove that you have a business that will scale. So I don't know what the biggest mistake will be, but we think the biggest outcomes will come from companies that have figured out what their business model is.

Thanks to Affinity for having me on The Cap Table, and we'll see you on the next one.